INSM raises peak sales guidance to $14 billion across three products
INSM raised peak sales guidance to $14 billion across three products. BRINSUPRI and TPIP revisions were driven by strong launch metrics and expanded indications, with BRINSUPRI launch outperforming analogs.
Peak sales guidance was raised to $14 billion across three products, with BRINSUPRI and TPIP both seeing significant upward revisions based on strong launch metrics and expanded indications. The launch of BRINSUPRI is outperforming analogs, supported by high payer approval and robust patient access…